News

Antonio Torrelo, MD, emphasizes that genetic testing enhances—but never replaces—clinical judgment in pediatric dermatology.

Doris Day, MD, reframes anti-aging: support fibroblasts, longevity pathways, lifestyle and smart fillers for healthier skin quality.

At SBS 2026, Karan Lal, MD, and Mohammad Goldust, MD, reveal how social media and AI reshape dermatology trust and care.

Phase 2 BEACON study shows brepocitinib rapidly clears cutaneous sarcoidosis lesions with strong CSAMI gains and tolerability, as Priovant readies phase 3 program.

David Cotter, MD, PhD, underscored the importance of incorporating quality-of-life and mental health measures into psoriasis clinical trials.

Catch up on coverage from the first day of South Beach Symposium 2026.

At MOPD 2026, Nanette Silverberg, MD, and Lisa Swanson, MD, unpack teen AD, fragrance allergy, and social media skin care hype harming barriers.

At MOPD 2026, Kristina Derrick, MD, ScM, links teen acne to hormones and metabolism, highlighting PCOS clues and antiandrogen therapies.

Michael Gold, MD, shares insights on safer device use, peptides, GLP-1s, acne, hair therapies, and more.

MOPD 2026 brings together leading experts to review recent therapeutic advances and practical management strategies in pediatric dermatology.

As SBS kicks off in South Beach Miami, scroll through faces familiar to Dermatology Times presenting at the symposium.

Aminex Therapeutics has initiated a trial evaluating AMXT 1501 and DFMO, with implications for dermatologists managing advanced melanoma.

Sagimet and Ascletis shared denifanstat's 52-week safety results plus sustained improvements, highlighting a once-daily oral FASN inhibitor for acne.

Discover how Nutrafol Men 50+ addresses age-related hair loss in men, combining targeted ingredients for optimal scalp health and hair quality.

UCB shares 3-year BIMZELX (bimekizumab) data in HS, showing sustained hidradenitis suppurativa lesion clearance and major severity reductions.

Catch up on the latest research posters presented at last month's conferences, compiled all in one place for dermatology professionals.

La Roche-Posay and the Oncology Nursing Society mark World Cancer Day with a first-of-its-kind tool, improving cancer care in patients with skin of color.

Clinicians assess chronic urticaria prevalence and impact, revealing gaps in understanding and treatment that affect patient care and outcomes.

Explore innovative treatments for skin conditions, including lebrikizumab for pemphigus and low-level laser therapy for hair loss.

Almirall's sarecycline gains NMPA approval in China, offering a new oral treatment for moderate-to-severe acne, enhancing patient access and outcomes.

James Del Rosso, DO, discusses diagnosis and treatment of mastocytosis and inflammatory conditions.

AbbVie seeks FDA and EMA approval for upadacitinib, a potential breakthrough systemic treatment for non-segmental vitiligo in adults and adolescents.

The new therapy targets age-related hair loss with a unique formula, promoting thicker, healthier hair for men over 50.

The new hub for dermatology NPs and PAs offers education, community, and resources to enhance patient care and professional growth.

Fractional CO₂ laser treatment effectively reduces acne scars in Middle Eastern patients, balancing safety and efficacy for darker skin types.

Patient education and partner involvement significantly enhance melanoma detection, especially in underserved and skin-of-color populations, improving survival outcomes.

Explore the long-term efficacy of biologics for HS, highlighting bimekizumab's superior outcomes in managing this chronic condition.

Galderma's relabotulinumtoxinA (Relfydess) aims to revolutionize wrinkle treatments with rapid results and lasting effects, pending FDA approval.

Arcutis reveals promising phase 2 results for roflumilast cream in infants with AD, highlighting safety and potential efficacy.

Explore top dermatology conferences and meetings in February 2026 and let us know which ones you'll be attending!